In 1986, Professor Moussa Youdim and Professor John Feinberg, two researchers from the Faculty of Medicine at the Technion, approached Teva Pharmaceutical Industries. They conducted research on a specific molecule and proposed that Teva develop a drug for Parkinson’s disease based on their research. Teva’s chief scientist was enthusiastic and began promoting the development of the drug. Approximately 20 years later, the FDA approved Azilect, a drug that slows the progression of Parkinson’s disease, based on the research of Youdim and Feinberg. Until then, there was no treatment for Parkinson’s, despite efforts by eight pharmacological companies to find one. Azilect was like oxygen for Parkinson’s patients and significantly improves their lives.